Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
| ▸ | CCR8 | P51685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10017439 | 0.78 | EDNRB (0.37) | — | |
| SCHEMBL16260054 | 0.78 | GRM4 (0.35) | NUDT1 | |
| SCHEMBL19073173 | 0.77 | NOS3 (0.31) | — | |
| SCHEMBL10048540 | 0.77 | SCN9A (0.47) | — | |
| SCHEMBL8958798 | 0.77 | SCN9A (0.33) | — | |
| SCHEMBL10385800 | 0.74 | CYP1A2 (0.41) | — | |
| SCHEMBL8583850 | 0.74 | GAA (0.35) | — | |
| SCHEMBL10385773 | 0.74 | NUDT1 (0.33) | NUDT1 | |
| SCHEMBL12603734 | 0.72 | — | — | |
| SCHEMBL396081 | 0.72 | MAPK8 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119786736-A | Electrolyte additive composition, electrolyte and battery | 惠州亿纬锂能股份有限公司 | 2025-04-08 | — | — | CN | claimed |
| CN-116199679-A | Industrial preparation method of lamivudine | 吉斯凯(苏州)制药有限公司 | 2023-06-02 | — | — | CN | claimed |
| EP-1819718-A1 | DIFLUORONUCLEOSIDES AND PROCESS FOR PREPARATION THEREOF | Sicor Inc. (US) | 2007-08-22 | — | — | EP | claimed |
| US-20060173174-A1 | Difluoronucleosides and process for preparation thereof | SICOR, INC. | 2006-08-03 | — | — | US | claimed |
| WO-2006063105-A1 | DIFLUORONUCLEOSIDES AND PROCESS FOR PREPARATION THEREOF | SICOR INC. (US) | 2006-06-15 | — | — | WO | claimed |
| JP-1061495-A | — | — | None | — | — | JP | disclosed |
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-12454521-B2 | Targeted protein degradation | C4 THERAPEUTICS, INC. | 2025-10-28 | — | — | US | disclosed |
| WO-2025072862-A9 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2025-06-26 | — | — | WO | disclosed |
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| CN-119786736-A | Electrolyte additive composition, electrolyte and battery | 惠州亿纬锂能股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-119786736-A | Electrolyte additive composition, electrolyte and battery | 惠州亿纬锂能股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| US-4851423-A | Pharmaceutically active compounds | SCHERING CORPORATION (US) | 1989-07-25 | — | — | US | disclosed |
| EP-0300765-A2 | Process for preparing 2-deoxynucleosides | ETHYL CORPORATION (US) | 1989-01-25 | — | — | EP | disclosed |
| US-4594339-A | Veterinary medicine | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1986-06-10 | — | — | US | disclosed |
| EP-0010205-B1 | 5-SUBSTITUTED 1-(2'-DEOXY-2'-SUBSTITUTED-BETA-D-ARABINOFURANOSYL) PYRIMIDINE NUCLEOSIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Sloan-Kettering Institute For Cancer Research (US) | 1983-05-04 | — | — | EP | disclosed |
| US-4211773-A | VIRICIDES, ANTITUMOR AGENTS | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1980-07-08 | — | — | US | disclosed |
| EP-0010205-A1 | 5-Substituted 1-(2'-deoxy-2'-substituted-beta-D-arabinofuranosyl) pyrimidine nucleosides and pharmaceutical compositions containing them | Sloan-Kettering Institute For Cancer Research (US) | 1980-04-30 | — | — | EP | disclosed |
| US-4109078-A | N-(POLYSACCHARIDYL)-NITROGEN HETEROCYCLES, ESPECIALLY PYRIMIDINE OR PURINE BASES, AND PROCESS FOR THEIR PREPARATION | SCHERING AKTIENGESELLSCHAFT (DE) | 1978-08-22 | — | — | US | disclosed |
| US-4082911-A | PROCESS FOR THE PREPARATION OF NUCLEOSIDES | SCHERING AKTIENGESELLSCHAFT (DT) | 1978-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | PSMC3, PSMA6, ADRM1 | NUDT1 4795/4885CCR1 534/4885CCR5 1923/4885 |
| US-20060173174-A1 | Difluoronucleosides and process for preparation thereof | DUT, NUDT1, DPYD | NUDT1 2/4885CCR1 3039/4885CCR5 3583/4885 |
| US-12454521-B2 | Targeted protein degradation | STUB1, MDM2, UBE3A | NUDT1 4574/4885CCR1 4280/4885CCR5 4347/4885 |
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | NUDT1 325/4885CCR1 587/4885CCR5 2212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.